{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:48:29Z","timestamp":1774540109073,"version":"3.50.1"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010888","name":"Wuhan Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["20200202010016"],"award-info":[{"award-number":["20200202010016"]}],"id":[{"id":"10.13039\/501100010888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejphar.2020.173646","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T02:02:41Z","timestamp":1603504961000},"page":"173646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Recent progress of antiviral therapy for coronavirus disease 2019"],"prefix":"10.1016","volume":"890","author":[{"given":"Mengmeng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jishou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173646_bib1","first-page":"1","article-title":"Repurposing of CQ and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus","author":"Adeoye","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejphar.2020.173646_bib2","article-title":"Coronavirus (COVID-19) update","volume":"1","year":"2020","journal-title":"Daily Roundup May"},{"key":"10.1016\/j.ejphar.2020.173646_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2020.04.016","article-title":"COVID-19 coronavirus research has overall low methodological quality thus far: case in point for CQ\/HCQ","author":"Alexander","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ejphar.2020.173646_bib5","series-title":"The Seventh Edition of COVID-19 Diagnosis and Treatment Plan","author":"Authority","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173646_bib6","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1093\/jac\/dkaa190","article-title":"Lopinavir\/ritonavir in COVID-19 patients: maybe yes, but at what dose?","volume":"75","author":"Baldelli","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2020.173646_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2014 preliminary report","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"HCQ: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.ejphar.2020.173646_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173646_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of HCQ as postexposure prophylaxis for covid-19","author":"Boulware","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib11","series-title":"Experimental Treatment with Favipiravir for COVID-19: an Open-Label Control Study","author":"Cai","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173646_bib12","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib13","first-page":"145","article-title":"[The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]","volume":"41","author":"CDC","year":"2020","journal-title":"Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi"},{"key":"10.1016\/j.ejphar.2020.173646_bib14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.ejphar.2020.173646_bib15","first-page":"215","article-title":"[A pilot study of HCQ in treatment of patients with moderate COVID-19]","volume":"49","author":"Chen","year":"2020","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.ejphar.2020.173646_bib16","series-title":"The Diagnosis and Treatment Guidelines of Pneumonia Caused by Novel Coronavirus","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173646_bib17","article-title":"Coronavirus infections-more than just the common cold","author":"Ci","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2020.173646_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","article-title":"Ribavirin's antiviral mechanism of action: lethal mutagenesis?","volume":"80","author":"Crotty","year":"2002","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ejphar.2020.173646_bib19","article-title":"A trial of lopinavir\u2013ritonavir in covid-19","author":"Dalerba","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib20","doi-asserted-by":"crossref","first-page":"20053","DOI":"10.1074\/jbc.R700006200","article-title":"Type I interferon receptors: biochemistry and biological functions","volume":"282","author":"de Weerd","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2020.173646_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study","author":"Deng","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.ejphar.2020.173646_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25781","article-title":"The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China","author":"Ding","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejphar.2020.173646_bib23","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2020.173646_bib24","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1073\/pnas.1718806115","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Ferron","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2020.173646_bib25","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.3390\/ijms21103626","article-title":"Potential inhibitors for novel coronavirus protease identified by virtual screening of 606 million compounds","volume":"21","author":"Fischer","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2020.173646_bib26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173646_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: CQ phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"BioScience Trends"},{"key":"10.1016\/j.ejphar.2020.173646_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"HCQ and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2020.173646_bib29","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of HCQ in hospitalized patients with covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib30","article-title":"A patient with COVID-19 disease in a referral hospital in Iran: a typical case","author":"Ghiasvand","year":"2020","journal-title":"Infect. Disord. - Drug Targets"},{"key":"10.1016\/j.ejphar.2020.173646_bib31","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in patients with severe covid-19","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib32","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the lombardy region","volume":"323","author":"Grasselli","year":"2020","journal-title":"Italy. Jama"},{"key":"10.1016\/j.ejphar.2020.173646_bib33","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib34","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/0310057X0903700112","article-title":"Survival after massive HCQ overdose","volume":"37","author":"Gunja","year":"2009","journal-title":"Anaesth. Intensive Care"},{"key":"10.1016\/j.ejphar.2020.173646_bib36","article-title":"In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors","volume":"21","author":"Gurung","year":"2020","journal-title":"Gene Rep"},{"key":"10.1016\/j.ejphar.2020.173646_bib37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"Jama"},{"key":"10.1016\/j.ejphar.2020.173646_bib38","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejphar.2020.173646_bib39","series-title":"Therapeutic Use of CQ and HCQ in COVID-19 and Other Viral Infections: A Narrative Review","author":"Hashem","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173646_bib40","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1097\/QAD.0b013e328332c3a5","article-title":"How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials","volume":"23","author":"Hill","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ejphar.2020.173646_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.173646_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2575-3","article-title":"CQ does not inhibit infection of human lung cells with SARS-CoV-2","author":"Hoffmann","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173646_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2020.173646_bib44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","article-title":"Ritonavir","volume":"35","author":"Hsu","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2020.173646_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwaa113","article-title":"Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of CQ for the treatment of COVID-19","author":"Huang","year":"2020","journal-title":"National Science Review"},{"key":"10.1016\/j.ejphar.2020.173646_bib46","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jmcb\/mjaa014","article-title":"Treating COVID-19 with CQ","volume":"12","author":"Huang","year":"2020","journal-title":"J. Mol. Cell Biol."},{"issue":"Pt 10","key":"10.1016\/j.ejphar.2020.173646_bib47","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/0022-1317-79-10-2381","article-title":"The antiviral compound ribavirin modulates the T helper (Th) 1\/Th2 subset balance in hepatitis B and C virus-specific immune responses","volume":"79","author":"Hultgren","year":"1998","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ejphar.2020.173646_bib48","first-page":"31042","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173646_bib49","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0190-9622(88)70130-9","article-title":"Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate","volume":"18","author":"Ikeda","year":"1988","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2020.173646_bib50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejphar.2020.173646_bib51","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00003088-200443130-00002","article-title":"Practical guidelines to interpret plasma concentrations of antiretroviral drugs","volume":"43","author":"Kappelhoff","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2020.173646_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104874","article-title":"Nitazoxanide\/azithromycin combination for COVID-19: a suggested new protocol for early management","volume":"157","author":"Kelleni","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2020.173646_bib53","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1086\/378304","article-title":"Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada","volume":"37","author":"Knowles","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173646_bib54","series-title":"Remdesivir: First Approval","first-page":"1355","volume":"vol. 80","author":"Lamb","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173646_bib55","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3762\/bjoc.12.267","article-title":"Computational methods in drug discovery","volume":"12","author":"Leelananda","year":"2016","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.ejphar.2020.173646_bib56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1120","key":"10.1016\/j.ejphar.2020.173646_bib57","article-title":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study","volume":"S1198\u20131743X","author":"Lian","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejphar.2020.173646_bib58","first-page":"304","article-title":"Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis","volume":"130","author":"Lippi","year":"2020","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib59","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.abc1731","article-title":"Against pandemic research exceptionalism","volume":"368","author":"London","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173646_bib60","article-title":"Clinical efficacy of HCQ in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","volume":"369","author":"Mah\u00e9vas","year":"2020","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.ejphar.2020.173646_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2558-4","article-title":"HCQ use against SARS-CoV-2 infection in non-human primates","author":"Maisonnasse","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173646_bib62","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gut.35.4.569","article-title":"Fulminant hepatic failure secondary to HCQ","volume":"35","author":"Makin","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2020.173646_bib63","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of HCQ with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejphar.2020.173646_bib64","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2230.2001.00857-3.x","article-title":"Fatal toxic epidermal necrolysis associated with HCQ","volume":"26","author":"Murphy","year":"2001","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2020.173646_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25985","article-title":"The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections","author":"Musarrat","year":"2020","journal-title":"Journal of Medical Virology n\/a"},{"key":"10.1016\/j.ejphar.2020.173646_bib66","series-title":"Coronavirus Disease (COVID-19) Situation Report \u2013 148","author":"Organization","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173646_bib67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1345\/aph.18089","article-title":"Nelfinavir mesylate: a protease inhibitor","volume":"33","author":"Pai","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2020.173646_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice","volume":"32","author":"Pruijssers","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2020.173646_bib69","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area","author":"Richardson","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.ejphar.2020.173646_bib70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of CQ and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2020.173646_bib71","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612043383791","article-title":"CQ and HCQ as inhibitors of human immunodeficiency virus (HIV-1) activity","volume":"10","author":"Romanelli","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejphar.2020.173646_bib72","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with HCQ or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","author":"Rosenberg","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2020.173646_bib73","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173646_bib74","series-title":"The Effect of CQ, HCQ and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection","author":"Saleh","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173646_bib75","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of CQ on viral infections: an old drug against today's diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173646_bib76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of CQ","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejphar.2020.173646_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib78","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 Days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.ejphar.2020.173646_bib79","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib80","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"Sulkowski","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2020.173646_bib81","article-title":"HCQ in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.ejphar.2020.173646_bib82","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ejphar.2020.173646_bib83","article-title":"Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States","author":"Team","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib84","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/tmi.13383","article-title":"The COVID-19 epidemic","volume":"25","author":"Velavan","year":"2020","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ejphar.2020.173646_bib85","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.ejphar.2020.173646_bib86","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and CQ effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ejphar.2020.173646_bib87","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173646_bib88","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","volume":"14","author":"Wang","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.ejphar.2020.173646_bib89","series-title":"Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China","author":"Wang","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173646_bib90","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173646_bib91","first-page":"E012","article-title":"[Real-world efficacy and safety of lopinavir\/ritonavir and arbidol in treating with COVID-19 : an observational cohort study]","volume":"59","author":"Wen","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.ejphar.2020.173646_bib92","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa020","article-title":"Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak","volume":"27","author":"Wilder-Smith","year":"2020","journal-title":"J. Trav. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib93","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173646_bib94","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejphar.2020.173646_bib95","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejphar.2020.173646_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235302","article-title":"Family cluster of three recovered cases of pneumonia due to severe acute respiratory syndrome coronavirus 2 infection","volume":"13","author":"Xiong","year":"2020","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ejphar.2020.173646_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2020.05.012","article-title":"Arbidol\/IFN-\u03b12b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study","author":"Xu","year":"2020","journal-title":"Microb. Infect."},{"key":"10.1016\/j.ejphar.2020.173646_bib98","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","article-title":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus","volume":"318","author":"Yamamoto","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2020.173646_bib99","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2020.173646_bib100","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/cr.2012.165","article-title":"Anti-malaria drug CQ is highly effective in treating avian influenza A H5N1 virus infection in an animal model","volume":"23","author":"Yan","year":"2013","journal-title":"Cell Res."},{"key":"10.1016\/j.ejphar.2020.173646_bib101","first-page":"3390","article-title":"Clinical efficacy of lopinavir\/ritonavir in the treatment of Coronavirus disease 2019","volume":"24","author":"Ye","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2020.173646_bib102","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore","volume":"323","author":"Young","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.ejphar.2020.173646_bib103","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00011-020-01342-0","article-title":"The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients","volume":"69","author":"Yuan","year":"2020","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.ejphar.2020.173646_bib104","series-title":"Clinical Characteristics of 140 Patients Infected with SARS-CoV-2 in Wuhan, China","author":"Zhang","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173646_bib105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2020.173646_bib106","article-title":"COVID-19: a recommendation to examine the effect of HCQ in preventing infection and progression","author":"Zhou","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2020.173646_bib107","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173646_bib108","first-page":"30188","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","author":"Zhu","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.ejphar.2020.173646_bib109","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992030738X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992030738X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:47:29Z","timestamp":1757976449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992030738X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":108,"alternative-id":["S001429992030738X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173646","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress of antiviral therapy for coronavirus disease 2019","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173646"}}